A novel NKp80-based strategy for universal identification of normal, reactive and tumor/clonal natural killer-cells in blood.

Autor:	Morán-Plata FJ; Translational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC - University of Salamanca), and Department of Medicine, University of Salamanca, Salamanca, Spain.; Cytometry Service, NUCLEUS, University of Salamanca, Salamanca, Spain., Muñoz-García N; Translational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC - University of Salamanca), and Department of Medicine, University of Salamanca, Salamanca, Spain.; Cytometry Service, NUCLEUS, University of Salamanca, Salamanca, Spain., González-González M; Translational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC - University of Salamanca), and Department of Medicine, University of Salamanca, Salamanca, Spain.; Cytometry Service, NUCLEUS, University of Salamanca, Salamanca, Spain., Pozo J; Translational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC - University of Salamanca), and Department of Medicine, University of Salamanca, Salamanca, Spain.; Cytometry Service, NUCLEUS, University of Salamanca, Salamanca, Spain., Carretero-Domínguez S; Translational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC - University of Salamanca), and Department of Medicine, University of Salamanca, Salamanca, Spain.; Cytometry Service, NUCLEUS, University of Salamanca, Salamanca, Spain.; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain., Mateos S; Translational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC - University of Salamanca), and Department of Medicine, University of Salamanca, Salamanca, Spain.; Cell-purification Service, NUCLEUS, University of Salamanca, Salamanca, Spain., Barrena S; Translational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC - University of Salamanca), and Department of Medicine, University of Salamanca, Salamanca, Spain.; Cytometry Service, NUCLEUS, University of Salamanca, Salamanca, Spain., Belhassen-García M; Department of Internal Medicine, University Hospital of Salamanca, Salamanca, Spain.; Department of Infectious Diseases, University Hospital of Salamanca, Centro de Investigación de Enfermedades Tropicales de la Universidad de Salamanca (CIETUS), Salamanca, Spain., Lau C; Laboratory of Cytometry, Unit for Hematology Diagnosis, Department of Hematology, Hospital de Santo António (HSA), Centro Hospitalar Universitário do Porto (CHUP), Unidade Multidisciplinar de Investigação Biomédica, Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto (UMIB/ICBAS/UP), Porto, Portugal., Teixeira MDA; Laboratory of Cytometry, Unit for Hematology Diagnosis, Department of Hematology, Hospital de Santo António (HSA), Centro Hospitalar Universitário do Porto (CHUP), Unidade Multidisciplinar de Investigação Biomédica, Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto (UMIB/ICBAS/UP), Porto, Portugal., Santos AH; Laboratory of Cytometry, Unit for Hematology Diagnosis, Department of Hematology, Hospital de Santo António (HSA), Centro Hospitalar Universitário do Porto (CHUP), Unidade Multidisciplinar de Investigação Biomédica, Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto (UMIB/ICBAS/UP), Porto, Portugal., Yeguas A; Department of Hematology, University Hospital of Salamanca, Salamanca, Spain., Balanzategui A; Department of Hematology, University Hospital of Salamanca, Salamanca, Spain.; Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain., García-Sancho AM; Translational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC - University of Salamanca), and Department of Medicine, University of Salamanca, Salamanca, Spain.; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Department of Hematology, University Hospital of Salamanca, Salamanca, Spain.; Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain., Orfao A; Translational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC - University of Salamanca), and Department of Medicine, University of Salamanca, Salamanca, Spain.; Cytometry Service, NUCLEUS, University of Salamanca, Salamanca, Spain.; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain., Almeida J; Translational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC - University of Salamanca), and Department of Medicine, University of Salamanca, Salamanca, Spain.; Cytometry Service, NUCLEUS, University of Salamanca, Salamanca, Spain.; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.
Jazyk:	angličtina
Zdroj:	Frontiers in immunology [Front Immunol] 2024 Jul 08; Vol. 15, pp. 1423689. Date of Electronic Publication: 2024 Jul 08 (Print Publication: 2024).
DOI:	10.3389/fimmu.2024.1423689
Abstrakt:	Purpose: Natural killer (NK) cells are traditionally identified by flow cytometry using a combination of markers (CD16/CD56/CD3), because a specific NK-cell marker is still missing. Here we investigated the utility of CD314, CD335 and NKp80, compared to CD16/CD56/CD3, for more robust identification of NK-cells in human blood, for diagnostic purposes. Methods: A total of 156 peripheral blood (PB) samples collected from healthy donors (HD) and patients with diseases frequently associated with loss/downregulation of classical NK-cell markers were immunophenotyped following EuroFlow protocols, aimed at comparing the staining profile of total blood NK-cells for CD314, CD335 and NKp80, and the performance of distinct marker combinations for their accurate identification. Results: NKp80 showed a superior performance (vs. CD314 and CD335) for the identification of NK-cells in HD blood. Besides, NKp80 improved the conventional CD16/CD56/CD3-based strategy to identify PB NK-cells in HD and reactive processes, particularly when combined with CD16 for further accurate NK-cell-subsetting. Although NKp80+CD16 improved the identification of clonal/tumor NK-cells, particularly among CD56 - cases (53%), aberrant downregulation of NKp80 was observed in 25% of patients, in whom CD56 was useful as a complementary NK-cell marker. As NKp80 is also expressed on T-cells, we noted increased numbers of NKp80 + cytotoxic T-cells at the more advanced maturation stages, mostly in adults. Conclusion: Here we propose a new robust approach for the identification of PB NK-cells, based on the combination of NKp80 plus CD16. However, in chronic lymphoproliferative disorders of NK-cells, addition of CD56 is recommended to identify clonal NK-cells, due to their frequent aberrant NKp80 - phenotype. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Morán-Plata, Muñoz-García, González-González, Pozo, Carretero-Domínguez, Mateos, Barrena, Belhassen-García, Lau, Teixeira, Santos, Yeguas, Balanzategui, García-Sancho, Orfao and Almeida.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu